- Home
- CLYM vs AMRN Comparison
CLYM vs AMRN Comparison
Compare CLYM & AMRN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CLYM
- AMRN
- Stock Information
- Founded
- CLYM 2018
- AMRN 1989
- Country
- CLYM United States
- AMRN Ireland
- Employees
- CLYM N/A
- AMRN N/A
- Industry
- CLYM
- AMRN Biotechnology: Pharmaceutical Preparations
- Sector
- CLYM
- AMRN Health Care
- Exchange
- CLYM NYSE
- AMRN Nasdaq
- Market Cap
- CLYM 242.8M
- AMRN 236.4M
- IPO Year
- CLYM 2021
- AMRN 1993
- Fundamental
- Price
- CLYM $3.79
- AMRN $0.56
- Analyst Decision
- CLYM
- AMRN Hold
- Analyst Count
- CLYM 0
- AMRN 2
- Target Price
- CLYM N/A
- AMRN N/A
- AVG Volume (30 Days)
- CLYM 331.1K
- AMRN 959.8K
- Earning Date
- CLYM 11-22-2024
- AMRN 10-30-2024
- Dividend Yield
- CLYM N/A
- AMRN N/A
- EPS Growth
- CLYM N/A
- AMRN N/A
- EPS
- CLYM N/A
- AMRN N/A
- Revenue
- CLYM N/A
- AMRN $241,021,000.00
- Revenue This Year
- CLYM N/A
- AMRN N/A
- Revenue Next Year
- CLYM N/A
- AMRN N/A
- P/E Ratio
- CLYM N/A
- AMRN N/A
- Revenue Growth
- CLYM N/A
- AMRN N/A
- 52 Week Low
- CLYM $2.35
- AMRN $0.56
- 52 Week High
- CLYM $11.55
- AMRN $1.37
- Technical
- Relative Strength Index (RSI)
- CLYM N/A
- AMRN 40.80
- Support Level
- CLYM N/A
- AMRN $0.56
- Resistance Level
- CLYM N/A
- AMRN $0.64
- Average True Range (ATR)
- CLYM 0.00
- AMRN 0.04
- MACD
- CLYM 0.00
- AMRN -0.00
- Stochastic Oscillator
- CLYM 0.00
- AMRN 11.26
About CLYM CLIMB BIO INC
Climb Bio Inc is a clinical-stage biotechnology company developing therapeutics for patients with immune-mediated diseases. its lead product candidate, budoprutug, is an anti-CD19 monoclonal antibody that has demonstrated B-cell depletion and has the potential to treat a broad range of B-cell-mediated diseases.
About AMRN Amarin Corporation plc
Amarin Corp PLC is a biopharmaceutical company. It is focused on the commercialization and development of therapeutics to improve cardiovascular, or CV, health and reduce CV risk. Its commercialized product includes Vascepa.